NMT Medical Announces New Organizational Structure In Its European Operations

BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- NMT Medical, Inc. , an advanced medical technology company that designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks, announced today the reorganization of its European operations in anticipation of the final results from its MIST (Migraine Intervention with STARFlex(R) Technology) clinical study, which are expected to be available in late March or early April 2006.

As part of the initiative, the Company is promoting Brad Ryno to Vice President, Worldwide Sales and Geoff Fournie to Vice President, Clinical Development, Europe. Ryno rejoined the Company in June 2004 as Director, Commercial Development, North America after having spent three years with NMT’s former neurosciences division. Fournie joined NMT in June 2002 as Director, Commercial Development, Europe.

Commenting on the reorganization, John E. Ahern, President and Chief Executive Officer, said, “Brad and Geoff have been key contributors in helping NMT advance its leadership position in the patent foramen ovale (PFO) closure market. Their newly created positions recognize both the value of their contributions and the importance the Company is placing on building our European sales and clinical infrastructure.”

“We are anticipating positive results from our MIST clinical trial in the United Kingdom,” said Ahern. “In advance of these results, the Company has made the strategic decision to increase its investment now in what we view as our next emerging marketplace -- PFO closure for migraine headache treatment in Europe.”

Under the new organizational structure, Mr. Ryno will have responsibility for the worldwide sales group currently covering Europe, the United States, Canada and Mexico. He will be tasked with expanding the current European sales organization to create and respond to the anticipated increase in demand for PFO closure related to an expected positive MIST outcome in early 2006.

Mr. Fournie, who was instrumental in facilitating the MIST, BEST (BioSTAR(TM) Evaluation STudy) and MIST III studies in Europe, will be given an expanded role to also include procedure reimbursement, patient referral and other initiatives to build acceptance of PFO closure procedures with our STARFlex(R) and BioSTAR(TM) technologies.

About NMT Medical, Inc.

NMT Medical is an advanced medical technology company that designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks through minimally invasive, catheter- based procedures. NMT Medical is investigating the potential connection between a common cardiac defect called a PFO and brain attacks such as migraine headaches, stroke and transient ischemic attacks (TIAs). A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 20,000 PFOs have been closed globally with NMT’s minimally invasive, catheter-based implant technology.

The prevalence of migraines in the United States is about 10%. Of the 28 million migraine sufferers in America, those who experience aura and have a PFO may represent a three million patient subset. Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and 500,000 Americans experience a TIA.

The Company also serves the pediatric interventional cardiologist with a broad range of cardiac septal repair implants delivered with nonsurgical catheter techniques. For more information about NMT Medical, please visit http://www.nmtmedical.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements -- including statements regarding the timing and outcome of the Company’s MIST III, MIST and BEST trials, the expansion of the Company’s market opportunities, including migraines and any other new applications for the Company’s technology or products, and regulatory approvals for the Company’s products -- involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. Factors that may cause such a difference include, but are not limited to, the Company’s ability to develop and commercialize new products, a potential delay in the regulatory process with the U.S. Food and Drug Administration and foreign regulatory agencies, as well as risk factors discussed under the heading “Certain Factors That May Affect Future Results” included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the period ended September 30, 2005, and subsequent filings with the U.S. Securities and Exchange Commission.

Contact: John E. Ahern President and Chief Executive Officer NMT Medical, Inc. (617) 737-0930 jea@nmtmedical.com

NMT Medical, Inc.

CONTACT: John E. Ahern, President and Chief Executive Officer of NMTMedical, Inc., +1-617-737-0930, jea@nmtmedical.com

MORE ON THIS TOPIC